Debate: Can biomarkers beyond MSI direct immunotherapy in GI malignancies? - No

Novel therapies beyond immunotherapy for GI MalignanciesПодробнее

Debate: Do biomarkers have a role in the adjuvant setting? - NoПодробнее

Predictive biomarkers for immunotherapy in upper GI cancersПодробнее

Dr. Saab on Immunotherapy in MSI-H GI MalignanciesПодробнее

Debate: MSI High Colon Cancer - ImmunotherapyПодробнее

Perioperative immunotherapy and surgery for treating MSI-high esophagogastric tumorsПодробнее

Dr. Nandini Menon: Biomarkers for Predicting Immunotherapy Efficacy (Non-PD-L1/MSI/TMB) | CRSFПодробнее

S3E05: Beyond Biomarkers: Calling All Data ScientistsПодробнее

MSI-high as a biomarker for immunotherapy in perioperative settingsПодробнее

MSI as a key immunotherapy biomarker in colon cancerПодробнее

Immune checkpoint inhibitors: recent progress and potential biomarkers - 3ii PD-L1 OverexpressionПодробнее

Update: Immunotherapy in GI cancersПодробнее

Role of Genomics in Identifying Biomarkers for Response and Resistance to Anti-Cancer ImmunotherapyПодробнее

Discover the link between MSI Instability and Immunotherapy in cancer treatment 🔬🎗️Подробнее

The role of neoadjuvant immunotherapy in MSI-high gastric cancerПодробнее

Marwan Fakih, MD, on whether MSI-high is a “must-have” biomarker for CRC patientsПодробнее

Immune checkpoint inhibitors: recent progress and potential biomarkers - 3iii PD-L1 OverexpressionПодробнее

Immune checkpoint inhibitors: recent progress and potential biomarkers - 3iv PD-L1 OverexpressionПодробнее